CA-XPRIZE
8.4.2020 14:02:04 CEST | Business Wire | Press release
XPRIZE , the global leader in incentivized prize competitions, in partnership with ANA , Japan’s 5-star airline, announce Avatars Inc , a unique online anthology that blends original science fiction stories with a writing competition to imagine novel use-cases of telepresence technology in the future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200408005209/en/
The anthology, edited by Ann VanderMeer, includes 24 original pieces by high-profile authors including James SA Corey, Adrian Tchaikovsky, Tade Thompson, Pat Cadigan, JY Yang, Ken Liu, Charles Yu, Paul McAuley, K Chess, Johanna Sinisalo, and Aliette de Bodard.
The premise for the anthology is as follows:
Established in 2038, Avatars Inc is the world’s leading producer of robotic avatar systems that can transport a human’s senses, actions, and presence to a remote location in real time. For the next few decades, they developed hundreds of avatar models and enabled millions of operator-hours. In 2080, a campaign was underway to physically retrieve, preserve and archive the memories from their most valuable units. We have been searching the world, and even deep into the solar system, to acquire the chips that contain avatar memories spanning the 21st century. These are those memories.
The short story contest is open through May 8, 2020 and is open to anyone over the age of 18 who submits an original story between 2,500 – 3,500 words, bringing to life a ‘missing’ avatar memory. Members of XPRIZE’s Science Fiction Advisory Council will vote on the finalist pieces to select the grand prize winner, who will then receive a prize package including a 3.2GHz 8-core Intel Xeon W Processor iMac Pro, a GoPro Hero7 Camera, Sony noise cancelling headphones, a 32GB Kindle Paperwhite, a JoneR Universal Translator, and more.
The fictional Avatars Inc was inspired by the real-life $10 million ANA Avatar XPRIZE , a four-year global competition focused on the development of an avatar system that can transport a human’s senses, actions, and presence to a remote location in real time. The competition was launched in March 2018 at South by Southwest (SXSW) in Austin.
“The world of Avatars Inc was made possible by the incredible partnership between XPRIZE and ANA and is intended to elevate the overall conversation about avatars among the general public, making the topic of avatars accessible, relevant and exciting, while creating demand and interest in the technologies that will result from the ANA Avatar XPRIZE,” said David Locke, Prize Lead of the ANA Avatar XPRIZE.
As of January 2020, a total of 77 teams from 19 countries qualified to compete. In March 2022, up to 20 teams will compete in the finals, which will include performance tests based on specific tasks that showcase the application of avatar technologies across several use-case scenarios. The first-place winner will receive $5 million.
To explore the world of Avatars Inc, and to submit your short story, visit http://www.avatars.inc .
About XPRIZE
XPRIZE, a 501(c)(3) nonprofit, is the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges. Active competitions include the $20 Million NRG COSIA Carbon XPRIZE, the $10 Million Rainforest XPRIZE, the $10 Million ANA Avatar XPRIZE and the $5 Million IBM Watson AI XPRIZE. For more information, visit xprize.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200408005209/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
